Edition:
United States

Profile: Alkermes Plc (ALKS.O)

ALKS.O on Nasdaq

50.37USD
22 Sep 2017
Change (% chg)

$0.03 (+0.06%)
Prev Close
$50.34
Open
$50.42
Day's High
$50.64
Day's Low
$50.04
Volume
385,423
Avg. Vol
790,937
52-wk High
$63.40
52-wk Low
$41.93

Alkermes plc is a biopharmaceutical company. The Company is engaged in the researching, developing and commercializing pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. The Company has a portfolio of marketed drug products and a clinical pipeline of products that address central nervous system (CNS) disorders, such as schizophrenia, depression, addiction and multiple sclerosis (MS). The Company's products include ARISTADA, VIVITROL, INVEGA SUSTENNA, XEPLION, INVEGA TRINZA, TREVICTA, RISPERDAL CONSTA, AMPYRA, FAMPYRA, BYDUREON, Aripiprazole lauroxil, ALKS 5461, ALKS 3831, ALKS 8700, ALKS 6428, ALKS 4230 and ALKS 7119. The Company's product platforms include injectable extended-release microsphere technology, LinkeRx technology, NanoCrystal technology and oral controlled release (OCR) technology. ARISTADA is an extended-release intramuscular injectable suspension for the treatment of schizophrenia.

Company Address

Alkermes Plc

Connaught HSE, 1 Burlington Road
DUBLIN     00000
P: +3531.7728000

Company Web Links